Welcome guest, is this your first visit? Click the "Create Account" button now to join.
Results 1 to 4 of 4
  1. #1
    Agrohomerve Guest

    Default ACRX (Mcap $54 M) 3x DRUGS IN PHASE 3 // RESULTS THIS MONTH =500% Potential !!!

    This unknowm lof float monster will fly into double digits once the investors discover this Goldmine . FIRST PHASE 3 RESULTS THIS MONTH THIS WILL PUSH THIS LOW FLOAT ROCKET TO $5-6 EASILY .

  2. Default

    ACRX has 3x Products in Phase 3 two of them have BLOCKBUSTER POTENTIAL . Institutions & Management bought over 560K shrs for $3.40 which is much higher from current huge bargain level of $2.89 .


    AcelRx Pharma (ACRX)

    Mcap: $54 M
    Cash: $24 M

    Price: $2.89

    Shares Out : 19.5 M SHRS (LOW FLOAT :ONLY 6.4 M SHRS)

    Great Pipeline:
    http://www.acelrx.com/


    Insider buying:
    http://www.secform4.com/insider-trading/1427925.htm


    Lots of Institutions buying :
    http://data.cnbc.com/quotes/ACRX/tab/8

  3. #3
    AInenue Guest

    Default

    Study of Sublingual Sufentanil NanoTab® PCA System vs. IV PCA Morphine for Post-Operative Pain

    -In this open-label study, the Sufentanil NanoTab PCA System also demonstrated statistical superiority to IV PCA morphine for primary endpoint of Patient Global Assessment of method of pain control
    - Nurses and patients rated Sufentanil NanoTab PCA System higher for Overall Satisfaction and Ease of Care compared to IV PCA morphine
    - AcelRx to conduct conference call and webcast today, November 15, at 8:00 a.m. EST (5:00 a.m. PST) to discuss top-line results in detail

  4. #4
    Airbladebzr Guest

    Default

    Genuity, who rated the company a Buy at current levels and set an $8.00/share price target. The Redwood City, California-based company is "a development stage specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain. The company is developing its lead product candidate, ARX-01, which is a Sufentanil NanoTab PCA system that is in Phase III clinical trials for acute post-operative pain".
    Analysts at Canaccord recently noted ""We're assuming coverage of AcelRx and setting a price target of $8 ahead of key data that could boost confidence in lead drug ARX-01 for post-operative analgesia using the company's transmucosal sufentanil-based drug device therapy," analyst Randall Stanicky said. "Market potential is sizable and we like the risk/reward, for those with risk appetite, ahead of important year-end data. Focus on the Phase III data comparator data to IV PCA morphine, the current standard of care, as the key catalyst which we expect over the next month or so." If the company can present positive year-end data in terms of both earnings and clinical data we could see some very significant upside.

 

 

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •